Plasminogen activator inhibitor type 2 is expressed in keratinocytes during re-epithelialization of epidermal defects

British Journal of Dermatology

Volumn 138, Issue 1, 1998, Pages 22-28

  Bechtel, M J ^a   Wysocki, N S ^a   Heidtmann, A ^a   Stark, H J ^b   Fusenig, N ^b   Kramer, M D ^a   Schaefer, B M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2;

ARTICLE; CELL DENSITY; CORRELATION FUNCTION; EPITHELIZATION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; SKIN DEFECT;

BLOTTING, NORTHERN; BURNS; CELL CULTURE TECHNIQUES; EPIDERMIS; EPITHELIUM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; KERATINOCYTES; MALE; PEMPHIGUS; PLASMINOGEN ACTIVATOR INHIBITOR 2; RNA, MESSENGER; WOUND HEALING;

EID: 0031909920     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02021.x     Document Type: Article

References (38)

1. Morioka S, Singer HS, Hashimoto K et al. Epidermal plasminogen activator: characterisation, regulatory mechanisms and possible role in skin disease. Rec Adv Dermatol 1986; 7: 53-67.
2. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65.
3. Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/ plasmin system. J Clin Invest 1991; 88: 1067-72.
4. Reinartz J, Batrla R. Boukamp P et al. Binding and activation of plasminogen at the surface of human keratinocytes. Exp Cell Res 1993; 208: 197-208.
5. Burge SM, Marshall JM, Cederholm-Williams SA. Plasminogen binding sites in normal human skin. Br J Dermatol 1992; 126: 35-41.
6. Del Rosso M, Fibbi G, Pucci M et al. Modulation of surface-associated urokinase: binding, interiorization, delivery to lysosomes, and degradation in human keratinocytes. Exp Cell Res 1991; 193: 346-55.
7. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15: 105-11.
8. Reinartz J, Link J, Todd RF, Kramer MD. The receptor for urokinase-type plasminogen activator of a human keratinocyte line HaCaT. Exp Cell Res 1994; 214: 486-98.
9. Jensen PJ, Michelle J, Baird JM. Urokinase and tissue type plasminogen activators in human keratinocyte culture. Exp Cell Res 1990; 187: 162-9.
10. Hashimoto K, Singer KH. Lide WB et al. Plasminogen activator in cultured human epidermal cells. J Invest Dermatol 1983; 81: 424-9.
11. Hashimoto K, Wun T-C, Baird J et al. Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor. J Invest Dermatol 1989; 92: 310-15.
12. Grondahl-Hansen J, Lund LR. Ralfkiaer E et al. Urokinase-and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol 1988; 90: 790-5.
13. Rømer J, Lund LR, Eriksen J et al. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds. J Invest Dermatol 1991; 97: 803-11.
14. Rømer J, Lund LR. Eriksen J et al. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during reepithelialization of mouse skin wounds. J Invest Dermatol 1994; 102: 519-22.
15. Venning VA, Wojnarowska F, Cederholm-Williams SA. An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. Clin Exp Dermatol 1993; 18: 119-23.
16. Bechtel MJ, Schaefer BM, Kramer MD. Plasminogen activator inhibitor type-2 in lesional epidermis of lupus erythematosus. Br J Dermatol 1996; 134: 411-19.
17. Lyons-Giordano B, Loskutoff D. Chen C-SJ et al. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 1994; 101: 105-12.
18. Schaefer BM, Stark HJ, Fusenig NE et al. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Exp Cell Res 1995; 220: 415-23.
19. Reinartz J, Schaefer BM, Bechtel MJ, Kramer MU. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 1996; 223: 91-101.
20. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975; 6: 331-44.
21. Foekens JA, Buessecker F, Peters HA et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-7.
22. Buessecker F, Reinartz J, Schirmer U, Kramer MD. Enzyme-linked immunosorbent assays for plasminogen activators. J Immunol Methods 1993; 162: 193-200.
23. Osada H, Yamada C, Miwa K et al. An assay system for the modulators of plasminogen activation on the cell surface. Thromb Res 1991; 62: 519-50.
24. Bechtel MJ, Reinartz J, Rox JM et al. Upregulation of cell-surface-associated plasminogen activation in cultured keratinocytes by interleukin-1b and tumor necrosis factor-α. Exp Cell Res 1996; 223: 395-404.
25. Mayer M. Biochemical and biological aspects of the plasminogen activator system. Clin Biochem 1990; 23: 197-211.
26. Jensen PJ, Baird JM, Morioka S et al. Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 1988; 90: 777-82.
27. Hibino T, Izaki S, Ohkuma M et al. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental-type PAI-2. FEBS Lett 1988; 231: 202-6.
28. Chen C-SJ, Lyons-Giordano B, Lazarus GS, Jensen PJ. Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system. J Cell Sci 1993; 106: 45-53.
29. Jensen PJ, Wu Q, Janowitz P et al. Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res 1995; 217: 65-71.
30. Ellis V, Wun T-C, Behrendf N et al. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 1990; 265: 9904-8.
31. Del Rosso M, Fibbi G, Dini G et al. Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J Invest Dermatol 1990; 94: 310-16.
32. Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-4.
33. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 1995; 270: 27894-904.
34. Frisch SM, Francis H, Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-26.
35. Ruoslahti E, Reed CJ. Anchorage dependences, integrins, and apoptosis. Cell 1994; 77: 477-87.
36. Matsue H, Kobayashi H, Hosokawa T et al. Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes. Arch Dermatol Res 1995; 287: 315-20.
37. Stoof T, Boorsma D, Nickoloff B. Keratinocytes and immunological cytokines. In: The Keratinocyte Handbook (Leich I, Lane B, Watt F, eds). Cambridge: Cambridge University Press, 1994; 365-99.
38. Polakowska RR, Piacentini M, Bartlett R et al. Apoptosis in human skin development: morphogenesis, periderm and stem cells. Dev Dyn 1994; 199: 176-88.